Britannia Pharmaceuticals Ltd.

Privately held: no public share price

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Approved
Dopamine receptor (non-ergoline agonist)Small molecule
Parkinson's Disease
Approved
Dopamine receptor (non-ergoline agonist)Small molecule
Parkinson's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.